Clinical trial · Observational
Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil
NCT05034393CI-TRIAL-00070259BRAVEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with de novo or recurrent HR-positive HER2-negative mBC
- description
- Patients diagnosed with de novo or recurrent HR-positive HER2-negative mBC from January 2018 to December 2020
Primary outcomes (1)
- measure
- The proportion of type of first-line treatment
- timeFrame
- from January 2018 to December 2020
Secondary outcomes (10)
- measure
- The PFS, defined as time from treatment start until progression (by image or physical exam) or death
- timeFrame
- from January 2018 to December 2020
- measure
- First-line treatment according to the drug name by type of health care coverage (public vs private)
- timeFrame
- from January 2018 to December 2020
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women ≥18 years old * Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer * Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3 * HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018 * Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020 * Public health system or private health system Exclusion Criteria: * Male Breast Cancer * First-line treatment for mBC received through clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.